ArticleOncogene2010
Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53.
Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 45 citations in OpenAlex.
- Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer's disease.Translational neurodegeneration · 2025Article
- EAF2: a tumor suppressor gene with multi-aspect functions.Frontiers in pharmacology · 2024Review
- Prostate tumor markers: diagnosis, prognosis and management.Genetics and molecular biology · 2024Article
- Hippo signaling and histone methylation control cardiomyocyte cell cycle re-entry through distinct transcriptional pathways.PloS one · 2023Article
- EAF2 loss induces prostatic intraepithelial neoplasia from luminal epithelial cells in mice.American journal of clinical and experimental urology · 2020Article
- Genomic signature of parity in the breast of premenopausal women.Breast cancer research : BCR · 2019Article
- Anti-apoptotic factor Birc3 is up-regulated by ELL2 knockdown and stimulates proliferation in LNCaP cells.American journal of clinical and experimental urology · 2019Article
- Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure.Frontiers in cardiovascular medicine · 2019Review
- EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer.Neoplasia (New York, N.Y.) · 2018Article
- Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice.Endocrinology · 2017Article
- Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia.The Journal of endocrinology · 2017Article
- EAF2 regulates DNA repair through Ku70/Ku80 in the prostate.Oncogene · 2017Article
- Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells.Oncotarget · 2016Article
- Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer.International urology and nephrology · 2016Article
- FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.The Prostate · 2015Article
- Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche.Ecancermedicalscience · 2015Article
- Chemopreventive apigenin controls UVB-induced cutaneous proliferation and angiogenesis through HuR and thrombospondin-1.Oncotarget · 2014Article
- MBASED: allele-specific expression detection in cancer tissues and cell lines.Genome biology · 2014Article
- Invoking the power of thrombospondins: regulation of thrombospondins expression.Matrix biology : journal of the International Society for Matrix Biology · 2014Review
- Identification of a genetic interaction between the tumor suppressor EAF2 and the retinoblastoma protein (Rb) signaling pathway in C. elegans and prostate cancer cells.Biochemical and biophysical research communications · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Inactivation of U19/EAF2 has been shown previously to lead to tumorigenesis in multiple organs; however, the mechanism of U19/EAF2 tumor suppression remains unclear. In this paper, we report that the expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is down-regulated in the prostate and liver of U19/EAF2 knockout mouse. The U19/EAF2 knockout liver displayed increased CD31-positive blood vessels, suggesting that the TSP-1 down-regulation can contribute to increased angiogenesis. TSP-1 is reported to be a p53-target gene and p53 is a known binding partner of ELL, which binds to U19/EAF2. Here, we show that U19/EAF2 can co-localize and co-immunoprecipitate with p53 in transfected cells. In a TSP-1 promoter-driven luciferase reporter assay, p53 transfection suppressed the TSP-1 promoter activity and U19/EAF2 co-transfection blocked the p53 suppression of TSP-1 promoter. However, U19/EAF2 transfection alone had little or no effect on the TSP-1 promoter. The above observations together suggest that U19/EAF2 regulates the expression of TSP-1 via blocking p53 repression of the TSP-1 promoter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.